DanielJLindnerMDPhD
General Surgery • Cleveland, OHAssistant Professor, Molecular Medicine, Case Western Reserve University School of Medicine
Dr. Lindner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Cleveland Clinic Main Campus
9500 Euclid Avenue
Cleveland, OH 44195Phone+1 216-445-0548
Education & Training
Georgetown University School of MedicineClass of 1981
Publications & Presentations
PubMed
- 8 citationsKDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer.Hong Qiu, Vladimir Makarov, Jennifer K Bolzenius, Angela Halstead, Yvonne Parker
Cancer Research. 2023-03-15 - 47 citationsRuxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis.Ali Tabarroki, Daniel J. Lindner, Valeria Visconte, Li Zhang, H. J. Rogers
Leukemia. 2014-01-10 - 56 citationsGene deletion of inositol hexakisphosphate kinase 2 predisposes to aerodigestive tract carcinoma.Bei H. Morrison, Rebecca M. Haney, Eric Lamarre, Judith A. Drazba, Glenn D. Prestwich
Oncogene. 2009-06-25
Abstracts/Posters
- Hypomethylating Agent 5-Azacytidine Sensitizes Peripheral T-Cell Lymphoma to SLAMF7-Targeting Therapeutic Antibody, ElotuzumabDaniel Lindner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid NeoplasiaDaniel Lindner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
- The Kindlin2-p53-SerpinB2 Signaling Axis Is Required for Cellular Senescence in Breast CancerJuly 15th, 2020
CytoDyn Initiates Pre-Clinical Study of Leronlimab (PRO 140) to Prevent NASH with the Cleveland Clinic’s Dr. Daniel J. Lindner, M.D., Ph.D.May 13th, 2019
ASH 2018: Dec 1-4December 1st, 2017- Join now to see all
Grant Support
- Nitrosylcobalamin - A Novel Chemotherapeutic AgentNational Cancer Institute2004–2007
- Inositol Hexakisphosphate Kinase 2:Apoptosis RegulatorNational Cancer Institute2004–2006
- Inositol Hexakisphosphate Kinase 2:Apoptosis RegulatorNational Cancer Institute2003
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
